Altria Group sells tobacco and nicotine products to adult consumers in the United States, and it makes money the same way every time: a consumer buys a pack of Marlboro cigarettes, a tin of Copenhagen smokeless tobacco, a can of on! nicotine pouches, or an NJOY e-vapor device, uses the product up, and comes back to buy more. Philip Morris USA, Altria's cigarette subsidiary, is the largest cigarette company in the United States. Marlboro has been the top-selling cigarette brand in the country for over 50 years. That kind of brand loyalty, combined with the addictive nature of nicotine, means customers tend to keep buying even when times are tough. The diagram below traces where the money goes.
How Altria Makes Money
flowchart TD
A["Tobacco Leaf Suppliers
Domestic Growers"] --> B["Manufacturing
Cigarettes, Cigars, MST"]
C["Nicotine Material Suppliers"] --> D["Manufacturing
Oral Pouches, E-Vapor"]
B --> E["Product Portfolio
23.3B Revenue"]
D --> E
E -->|"Wholesalers
Retail Chains"| F["U.S. Consumer Sales
Age 21+"]
F --> G["Operating Cash Flow
9.3B"]
G --> H["R&D & Product Innovation
New Platforms"]
H --> E
G --> I["Capital Expenditures
Manufacturing"]
I --> B
I --> D
F --> J["Joint Venture Horizon
75% Economic Interest"]
J -->|"Upon FDA Auth"| H
Five years of financial data tell a clear story: revenue is slowly falling, but the business is getting more efficient as it shrinks. Revenue dropped from $25.1 billion in 2022 to $23.3 billion in 2025. That is a decline of about $1.8 billion over three years. Fewer people are smoking cigarettes in America, and that trend is not reversing.
Altria Annual Revenue (2022 to 2025)
Revenue in billions of dollars. The decline is steady and consistent across all four years.
Yet even as revenue falls, Altria's gross margin, the share of each dollar of revenue left after paying for the cost of making its products, has risen every single year. In 2022 it was about 56.8%. By 2025 it had climbed to about 62.5%. That means Altria is raising prices faster than its costs are rising, squeezing more profit out of each unit even as it sells fewer units overall.
Even as total revenue fell, Altria kept more of each dollar it earned. That spread widened every year from 2022 to 2025.
Free cash flow, the actual cash left over after the company pays for running and maintaining the business, has held up remarkably well despite the revenue slide. It came in at $8.1 billion in 2022 and $9.1 billion in both 2023 and 2025. That cash is what funds the dividend payments Altria is known for, and it is also what the company uses to reduce its debt load. Net debt fell from $22.5 billion in 2023 to $21.2 billion in 2025.
$9.1B
Free cash flow in 2025, matching the 2023 level despite two more years of revenue decline
The company is also running a restructuring program called Optimize and Accelerate, announced in October 2024, which involves centralizing work, outsourcing certain tasks, and automating processes. Altria expects this to deliver at least $600 million in cumulative savings by the end of 2029, though the estimated cost of making those changes has already risen from $125 million to $175 million.
2025
crisis
NJOY Write-Down: $1.26 Billion in Impairment Charges
Altria recorded $1.26 billion in non-cash impairment charges on its NJOY e-vapor business during 2025. The write-downs happened because illegal flavored e-vapor products, most of which never went through FDA review, flooded the market and crushed demand for NJOY's legal products. A patent lawsuit also resulted in an order banning the import and sale of NJOY ACE, the company's main e-vapor product, in the United States. These two problems together forced Altria to write down the value of NJOY's technology, trademarks, and goodwill by over a billion dollars in a single year.
The NJOY situation highlights a broader tension in Altria's story. The company's core cigarette business is in long-term structural decline. Cigarette shipment volume fell 10% in 2025 alone. Altria's answer to that problem is to build a portfolio of smoke-free nicotine products like e-vapor devices, oral nicotine pouches, and eventually heated tobacco sticks. But each of those paths carries its own serious risks.
What Is an FDA Marketing Granted Order?
In the United States, tobacco and nicotine products must go through a review process run by the Food and Drug Administration before they can legally be sold. If the FDA approves a product, it issues what is called a Marketing Granted Order, or MGO. Without one, a product is not supposed to be on store shelves. The problem is that many products are sold illegally without ever getting this approval, and enforcement has been slow.
The FDA can deny approval for any of Altria's smoke-free products or demand they be pulled from shelves at any time. Long review periods let competitors grab market share while Altria waits. Illegal flavored disposable e-vapor products, which Altria estimates make up roughly 70% of the e-vapor category, continue to drain customers away from legal products like NJOY. The company says it now expects enforcement against those illegal products to happen more slowly than it originally hoped.
~70%
Share of the e-vapor category Altria estimates is made up of products that have largely evaded FDA review, as of the 2025 annual report
What Are Heated Tobacco Sticks?
Heated tobacco sticks are a category of products that heat real tobacco without burning it, producing vapor instead of smoke. Altria has a joint venture called Horizon with Japan Tobacco to sell these products in the United States under the Ploom brand, with Marlboro-branded consumables made by PM USA. As of February 2026, no products from this joint venture were yet available in the U.S. market because FDA authorization had not been granted.
On the oral nicotine side, Altria's on! pouches are growing, but they face competition from synthetic nicotine pouch products that have started appearing in traditional tobacco stores without going through the standard regulatory process. The Skoal brand, part of the smokeless tobacco business, is showing signs of stress: its estimated fair value exceeded its carrying value by only about 7% in the most recent annual test, leaving little cushion before an impairment charge becomes possible.
Altria's entire business operates almost entirely within the United States. The company's 10-K says it generates substantially all of its revenue from domestic customers. That means any shift in U.S. regulation, consumer behavior, or enforcement policy hits the whole business at once, with no international revenue to cushion the blow.
Supply chain concentration adds another layer of risk. The company depends on a small number of manufacturing facilities and a limited set of suppliers for tobacco leaf, nicotine extract, aluminum, and wood tips. A disruption from a natural disaster, geopolitical conflict, or a supplier's financial failure could halt production of core products with few easy alternatives available quickly.
The Bet
Altria can raise prices on Marlboro and its other legacy tobacco products fast enough, for long enough, to keep generating massive free cash flow while the smoke-free business matures. That requires the cigarette decline to stay gradual rather than accelerating sharply, the FDA to eventually clear a path for NJOY and the Horizon heated tobacco products, and enforcement against illegal e-vapor products to improve enough to give legal products a fair share of the market. If the cigarette decline speeds up, if regulators block or delay the smoke-free portfolio, or if illegal products continue to dominate e-vapor shelves, the cash engine that funds everything else shrinks before the new businesses are ready to replace it.
Open question
Altria generates extraordinary cash from a shrinking core business and is trying to pivot toward smoke-free nicotine products before that core runs out of runway. The financial efficiency is real. The cash flows are real. But the NJOY write-downs in 2025 showed that the smoke-free transition is harder, slower, and more expensive than the company planned. The cigarette volume decline accelerated to 10% in 2025. The heated tobacco joint venture has not yet sold a single product in the United States. Can Altria build a smoke-free business big enough to matter before the Marlboro cash engine fades too far to support the effort?
Compiled · 10-K · FY2025
